KR102224965B1 - 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 - Google Patents

세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 Download PDF

Info

Publication number
KR102224965B1
KR102224965B1 KR1020167000554A KR20167000554A KR102224965B1 KR 102224965 B1 KR102224965 B1 KR 102224965B1 KR 1020167000554 A KR1020167000554 A KR 1020167000554A KR 20167000554 A KR20167000554 A KR 20167000554A KR 102224965 B1 KR102224965 B1 KR 102224965B1
Authority
KR
South Korea
Prior art keywords
cell
cancer
active ingredient
peptide
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167000554A
Other languages
English (en)
Korean (ko)
Other versions
KR20160029069A (ko
Inventor
김상재
Original Assignee
주식회사 젬백스앤카엘
김상재
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 젬백스앤카엘, 김상재 filed Critical 주식회사 젬백스앤카엘
Publication of KR20160029069A publication Critical patent/KR20160029069A/ko
Application granted granted Critical
Publication of KR102224965B1 publication Critical patent/KR102224965B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167000554A 2013-07-12 2014-07-11 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 Active KR102224965B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20130082265 2013-07-12
KR1020130082265 2013-07-12
KR1020130165071 2013-12-27
KR20130165071 2013-12-27
PCT/KR2014/006257 WO2015005723A1 (ko) 2013-07-12 2014-07-11 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트

Publications (2)

Publication Number Publication Date
KR20160029069A KR20160029069A (ko) 2016-03-14
KR102224965B1 true KR102224965B1 (ko) 2021-03-09

Family

ID=52280308

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167000554A Active KR102224965B1 (ko) 2013-07-12 2014-07-11 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트

Country Status (6)

Country Link
US (1) US9757473B2 (enExample)
EP (1) EP3020724A4 (enExample)
JP (1) JP6574175B2 (enExample)
KR (1) KR102224965B1 (enExample)
CN (1) CN105531284B (enExample)
WO (1) WO2015005723A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108841802B (zh) 2012-05-11 2023-06-09 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN104837859B (zh) 2012-09-19 2019-02-22 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
JP6517692B2 (ja) 2012-09-19 2019-05-22 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
KR20180004752A (ko) 2015-05-26 2018-01-12 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
WO2022240055A1 (ko) * 2021-05-14 2022-11-17 주식회사 레메디 화물분자 수송 도메인 rmad1, 이의 변이체, 재조합 화물분자 및 이를 이용한 화물분자 수송 방법
US20240252660A1 (en) * 2021-06-03 2024-08-01 Remedi Co., Ltd. Cargo molecule transduction domain rmmr1, variant thereof, recombinant cargo molecule, and method for transducing cargo molecule using same
CN120958034A (zh) 2023-02-23 2025-11-14 微肽技术有限公司 用于产生和纯化肽的方法和组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225027A1 (en) 2002-05-31 2003-12-04 Huang Jun Jian Telomerase reverse transcriptase fragments and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2294782A1 (en) * 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
WO2003038047A2 (en) * 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
EP2076531B1 (en) * 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
CN102321658A (zh) * 2011-07-20 2012-01-18 安徽农业大学 猪体细胞的重组蛋白诱变方法
KR101293620B1 (ko) * 2011-08-19 2013-08-13 국립암센터 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
KR20130082265A (ko) 2012-01-11 2013-07-19 스키너스 주식회사 조적벽체 내진보강 구조
KR101444199B1 (ko) * 2012-02-20 2014-09-30 대한민국 세포막 투과용 단백질 및 그 용도
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN110028554B (zh) * 2012-09-19 2023-04-07 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225027A1 (en) 2002-05-31 2003-12-04 Huang Jun Jian Telomerase reverse transcriptase fragments and uses thereof

Also Published As

Publication number Publication date
CN105531284B (zh) 2021-03-23
CN105531284A (zh) 2016-04-27
EP3020724A1 (en) 2016-05-18
US20160158374A1 (en) 2016-06-09
WO2015005723A1 (ko) 2015-01-15
US9757473B2 (en) 2017-09-12
JP6574175B2 (ja) 2019-09-11
JP2016523558A (ja) 2016-08-12
EP3020724A4 (en) 2017-01-18
KR20160029069A (ko) 2016-03-14

Similar Documents

Publication Publication Date Title
KR102224965B1 (ko) 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
JP7742390B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20240181090A1 (en) Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102201430B1 (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
US9937240B2 (en) Peptide having fibrosis inhibitory activity and composition containing same
CN112533640B (zh) 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向
RS56095B1 (sr) Fuziona belančevina protiv raka
CN117098770A (zh) 针对sort1的多肽化合物及其药物偶联物
CN117136066A (zh) Nectin-4靶向肽化合物及其药物偶联物
KR102774792B1 (ko) 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
KR102166549B1 (ko) 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
EP2797617B1 (en) Anti-tumor adjuvant therapy
JP2020501513A (ja) 治療用多標的コンストラクトおよびその使用
CN106928322B (zh) 一种具有抗脑缺血作用的融合多肽及其应用
CN104119444B (zh) 抗肿瘤融合蛋白及其制备方法和用途
KR102499767B1 (ko) 종양으로의 약물 전달을 위한 뉴로필린 1에 특이적으로 결합하는 종양 조직 침투성　펩타이드 및 이의 용도
CN114599375B (zh) 核酸递送促进剂
CN102277364A (zh) 融合蛋白LhFVII-LDP和强化融合蛋白LhFVII-LDP-AE及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6